Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression.

Lorena Catarina Del SantLuciana Maria SarinAna Cecília LuccheseEduardo Jorge Muniz MagalhãesMarco Aurélio TuenaCarolina NakahiraJosé Alberto Del PortoAcioly Luiz Tavares Lacerda Jair de Jesus Mari

Published in: Pharmaceuticals (Basel, Switzerland) (2022)

Our results suggest that repeated subcutaneous esketamine doses are safe and well-tolerated regarding their acute dissociative and psychotomimetic symptoms. Symptoms usually peak at 30 min and decrease at 60 min post-injection, returning to their pretreatment levels at 120 min. Dissociative symptoms do not correlate with antidepressant response.

Keyphrases

sleep quality
liver failure
respiratory failure
intensive care unit
physical activity
extracorporeal membrane oxygenation
ultrasound guided